NCT00992654
No Longer Available
Not Applicable
A Local, Multicentre, Open Label Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Human Immunodeficiency Virus (HIV)
- Sponsor
- ViiV Healthcare
- Status
- No Longer Available
- Last Updated
- 7 years ago
Overview
Brief Summary
The new protocol will allow the patients enrolled on A4001050 to have continuous access of Maraviroc and the treatment will not be interrupted until the drug is commercially available in India.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects who complete the A4001050 study and are continuing to derive benefit from Maraviroc.
- •Subjects who are willing and able to comply with scheduled visits, treatment plan and other study procedures.
Exclusion Criteria
- •Subjects who discontinued in A4001050 study.
- •Unable to provide consent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Expanded Access Program for Maraviroc At Multiple CentersHIV InfectionsNCT00426660ViiV Healthcare1,047
Approved For Marketing
Not Applicable
Olaratumab (LY3012207) Patient Access for Soft Tissue SarcomaSoft Tissue SarcomaNCT03994627Eli Lilly and Company
No Longer Available
Not Applicable
An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving MaravirocInfection, Human Immunodeficiency VirusNCT01776996ViiV Healthcare
No Longer Available
Not Applicable
A Compassionate Access Protocol For Those Patients Who Have Completed A4001029HIVNCT00801515ViiV Healthcare
Approved For Marketing
Not Applicable
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)Alagille SyndromeNCT04530994Mirum Pharmaceuticals, Inc.